A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis

To evaluate the effect of namilumab on the need for rescue treatment for worsening of sarcoidosis.

Study-ID: NCT05314517, 2021-004794-31

DZL Disease Area: DPLD

Study Type: Interventional

DZL Role: DZL recruiting center

Funding: Externally - industry

DZL Participating Sites: BREATH, TLRC

Start Date: 24.04.2023

Completion Date: 22.04.2024

Status: Closed

DZL recruiting center

Disease: Pulmonary Sarcoidosis

NCT Number: NCT05314517

EUCT/CTIS Number: 2021-004794-31